487 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
or epidemic diseases and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company … is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Other Disclaimers and Trademarks
The information
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Jan 24
Other Events
5:50pm
of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
1 Dec 23
Entry into a Material Definitive Agreement
8:25am
these forward-looking statements beyond the date of this report. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform
8-K/A
EX-99.1
tr3 x4gknze7
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
u94a3586 er
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
ab3mspc
18 Oct 23
Other Events
9:03am
8-K
EX-10.1
zr8eimradxdl
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
ioigu1 q9leqs5nav
18 Sep 23
Other Events
5:26pm
8-K
EX-99.1
1b4czyxcft4ktodwssgp
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
n7evvvwu p5w
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
a8nts72
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
8-K
EX-10.1
ym4besf2 kp6ubwlefa
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
425
w1vt d4m5h
3 Oct 22
Business combination disclosure
9:20am